Siemens Healthcare is one of the world’s largest suppliers of technology to the healthcare industry and a leader in medical imaging, laboratory diagnostics, and clinical IT. With around 44,000 employees worldwide and a presence throughout the world, Siemens Healthcare generated revenue worth 12.9 billion euros and profits of more than 2.1 billion euros in fiscal 2015.
Siemens Healthcare aspires to become the trusted partner of healthcare providers worldwide – the partner that they can rely on to help drive their clinical excellence, operational efficiency, and profitability. To live up to this ambition, we are committed to further developing our traditional strengths in the imaging and laboratory fields and to complementing them with new offerings. We will continuously expand our management, consulting, and digital services, and broaden our portfolio e.g. with advanced therapy solutions and molecular in-vitro diagnostic products.
Contact
Siemens Healthcare Nederland B.V.
Prinses Beatrixlaan 800
2595 BN Den Haag
Postbus 1 60 68
2500 BB Den Haag
Netherlands
Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As…
As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over…
Andreas Schuil, Vice President & General Manager EMEA at Orchard Therapeutics, discusses the company’s gene therapy for metachromatic leukodystrophy, a devastating ultra-rare paediatric disease. He highlights challenges in access, pricing…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
A century after insulin’s discovery transformed Type 1 diabetes from fatal to manageable, access remains deeply unequal. Writing exclusively for PharmaBoardroom, Access to Medicine Foundation CEO Jayasree Iyer explores why…
Philip Scheltens, Professor of Neurology and Partner and Head of the EQT Life Sciences Dementia Fund, reflects on the journey from founding the world’s first dedicated neurodegeneration investment fund to…
Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In…
The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs).…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
See our Cookie Privacy Policy Here
